News Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19 Staff September 11, 2023 Iframe sync Post navigation Previous: Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research ConferenceNext: Major shareholder announcement – BlackRock, Inc. More Stories Diagnostics EHR Healthcare immunotherapy News ModuleMD Continues to Strengthen Its Position in Allergy EHR Innovation with a New Generation of AI-Powered Technology Staff November 21, 2026 Healthcare News Pharmaceutical FlatRx Publishes a Dated Price Comparison of Compounded Tirzepatide at 27 U.S. Telehealth Programs Counted at a 10 mg Weekly Dose Staff November 21, 2026 News Regenecell outlines assessment priorities for U.S. patients exploring stem cell therapy in Mexico Staff November 21, 2026